As global competition within the GLP-1 landscape reaches a fever pitch, weight loss is no longer the sole objective; rather, cardiovascular-metabolic benefits and tolerability have emerged as key differentiators.
Recently, Borui Pharmaceutical announced positive top-line results from BGM0504-III-WL—a Phase III clinical trial evaluating BGM0504 Injection, its independently developed dual GLP-1/GIP receptor agonist. The data reveals that the drug not only demonstrated exceptional efficacy in terms of weight loss and waist circumference reduction but also exhibited superior comprehensive capabilities in cardiovascular-metabolic regulation. Furthermore, it boasted an extremely low discontinuation rate, and—remarkably—led to an increase rather than a decrease in bone mineral density. These results position BGM0504 as a strong contender to become the next "trump card" product in the GLP-1 market.